July 2, 2018
– Epigenomics plans to CE Mark mSEPT9 blood test for liver cancer by year-end 2018, enabling commercialization in Europe – Prospective U.S. trial for FDA submission […]
April 19, 2018
UTI panel covers 103 diagnostic targets 443-patient multi-center study demonstrates overall weighted average sensitivity of 95.6% at an overall weighted average specificity of 99.3%. Amsterdam, the […]
April 4, 2018
– First ever multiplex MDx test to be granted clearance by the FDA for this indication – Commercial launch in the U.S. expected this quarter Amsterdam, […]
April 4, 2018
– Second market authorization for Unyvero Cartridges this year in Singapore Amsterdam, the Netherlands, and Holzgerlingen, Germany, April 04, 2018; published at 11:30 am CEST — […]
March 6, 2018
– Award winner in “GoSiliconValley” competition by Austrian Economic Chambers – Support for business development in U.S. market Amsterdam, the Netherlands, San Diego, CA, USA, and […]
February 19, 2018
16 Feb 2018 – CEO Oliver Schacht from Curetis (EN Amsterdam:CURE) tells Proactive Investors their Unyvero Platform finds killer bugs in hospitals and tells doctors which […]
February 6, 2018
– Market authorization paves way for broader Unyvero commercial roll-out in ASEAN region through partner Acumen Research Laboratories – Near-term clinical validation study of first cartridge-based […]
January 8, 2018
– Review of the Unyvero System and Lower Respiratory Tract (LRT) Cartridge is nearing completion – U.S. commercial team and operational infrastructure in place Amsterdam, the […]
December 20, 2017
Dec 19, 2017 NEW YORK (GenomeWeb) – Epigenomics announced today that it has received CE-IVD marking for its blood-based lung cancer test Epi proLung. Epi proLung […]
